Published on IRCCS materno infantile Burlo Garofolo (https://www.burlo.trieste.it)

Home > Printer-friendly > EPIC Study: Impact Of Early Proactive Therapeutic Drug Monitoring On The Durability And Efficacy Of Infliximab Therapy In Pediatric Inflammatory Bowel Disease: A Multicenter Open-Label Randomized-Control Trial

EPIC Study: Impact Of Early Proactive Therapeutic Drug Monitoring On The Durability And Efficacy Of Infliximab Therapy In Pediatric Inflammatory Bowel Disease: A Multicenter Open-Label Randomized-Control Trial [1]

Tipo di studio: 
Studio clinico interventistico con farmaco
Specialita': 
Gastroenterologia e Dietologia
Descrizione: 
EPIC Study: Impact Of Early Proactive Therapeutic Drug Monitoring On The Durability And Efficacy Of Infliximab Therapy In Pediatric Inflammatory Bowel Disease: A Multicenter Open-Label Randomized-Control Trial
Codice EUDRACT: 
2021-003220-32
Codice Protocollo: 
EpicStudy
Natura dello studio: 
No Profit
Monocentrico/Multicentrico: 
Multicentrico - IRCCS Burlo Garofolo Partner
Fase: 
IV
Inizio studio: 
Lunedì, 1 Marzo, 2021
Sperimentatore Responsabile: 
Dott.ssa Sara Lega
Sponsor: 
IRCCS materno infantile Burlo Garofolo
Sesso paziente: 
Maschile - Femminile
EU Clinical Trials Register: 
https://www.burlo.trieste.it/2021-003220-32 [2]
Fascia di età paziente: 
Bambini (2-11 anni)
Adolescenti (12-17 anni)
Età specifica: 
≥ 6 anno e < 18 anni
Arruolamento categorie vulnerabili: 
Pazienti
Status studio: 
aperto
contenuto aggiornato il 31/03/2024 - 12:39:05

Source URL: https://www.burlo.trieste.it/epic-study-impact-early-proactive-therapeutic-drug-monitoring-on-durability-and-efficacy-infliximab-therapy-pediatric

Collegamenti
[1] https://www.burlo.trieste.it/epic-study-impact-early-proactive-therapeutic-drug-monitoring-on-durability-and-efficacy-infliximab-therapy-pediatric
[2] https://www.burlo.trieste.it/2021-003220-32